FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557095951> ?p ?o ?g. }

• W2557095951 abstract "Abstract New drugs and high dose therapy with auto-transplantation (auto-SCT) has improved prognosis of multiple myeloma (MM). New drugs are promising in upfront therapy while the role of maintenance is still debated. Thalidomide (thal) is an active drug in the treatment of myeloma, and is been investigated as first line therapy, the limit of this drug is the toxicity dependent dose and this determines a poor compliance. It could be useful in the control of minimal residual disease. We used low dose of thal as maintenance after autologous transplantation in patient with MM from January 2002 and here we bring our experience after six years of observation. From January 2002 to August 2008 17 patients (8 males and 9 females) with MM have been treated in our institution. Median age was 59,5 years (range 48–72). 10 were IgG, 3 IgA, 3 light chains and 1 plasma-cell leukaemia. Treatment was 4 cycles of VAD regimen followed by auto-SCT. 4/17 performed double auto-SCT. Three months after SCT these patients has begun the maintenance with thal 50 mg/die, to start thal maintenance 9 patients were in CR, 5 in PR and 3 in resistant disease and the median somministration of thal has been of 12 months (range 3–24 months). Median follow up from the beginning of maintenance therapy was 40 months (range 4–76) with 11/17 (64%) patients in CR or stable disease, with progression free survival (PFS) and overall survival (OS) projected at 75 months respectively of 53% and 51% from to start thal. In our experience we have observed a neurological toxicity (grade I–III) in the 65% of the patients but only 4 have had to suspend the treatment; a haematological toxicity of grade I in the 55% of the patients that have not behaved interruption of the treatment and finally in any case we have documented thrombotic episodes. Finally we have compared this group of patients with another group (18 patients) with the same clinical characteristics that we have observed in the same period but that have not effected maintenance with thal. In this last group 13/18 patients (72%) relapsed with median follow-up of 36 months (range 14–75) and median PFS and OS of 16 and 30 months respectively. The difference between the 2 groups is statistically significant for PFS (p: 0.003) and OS (p: 0.04). The median overall survival observed after progression, in the two groups, has been of 13 months in thal group and 17 months in the group of patients that have not effected the maintenance, this difference is not statistically different (p:0.06). In conclusion in 6 years of observation our experience has shown, even if the number of the patients is small, that maintenance with low doses of thal, after auto-transplantation, it not only has a good compliance but it improves the PFS and OS in this cohort and it doesn’t worsen the OS from the relapse." @default.
• W2557095951 created "2016-11-30" @default.
• W2557095951 creator A5000602610 @default.
• W2557095951 creator A5039744091 @default.
• W2557095951 creator A5041347112 @default.
• W2557095951 creator A5044869604 @default.
• W2557095951 creator A5054001250 @default.
• W2557095951 creator A5083031946 @default.
• W2557095951 creator A5084262338 @default.
• W2557095951 creator A5090939110 @default.
• W2557095951 date "2008-11-16" @default.
• W2557095951 modified "2023-10-01" @default.
• W2557095951 title "Six Years of Experience and Outcome with Maintenance Therapy with Very Low Dose Thalidomide after Auto-SCT in Multiple Myeloma" @default.
• W2557095951 doi "https://doi.org/10.1182/blood.v112.11.5208.5208" @default.
• W2557095951 hasPublicationYear "2008" @default.
• W2557095951 type Work @default.
• W2557095951 sameAs 2557095951 @default.
• W2557095951 citedByCount "0" @default.
• W2557095951 crossrefType "journal-article" @default.
• W2557095951 hasAuthorship W2557095951A5000602610 @default.
• W2557095951 hasAuthorship W2557095951A5039744091 @default.
• W2557095951 hasAuthorship W2557095951A5041347112 @default.
• W2557095951 hasAuthorship W2557095951A5044869604 @default.
• W2557095951 hasAuthorship W2557095951A5054001250 @default.
• W2557095951 hasAuthorship W2557095951A5083031946 @default.
• W2557095951 hasAuthorship W2557095951A5084262338 @default.
• W2557095951 hasAuthorship W2557095951A5090939110 @default.
• W2557095951 hasConcept C126322002 @default.
• W2557095951 hasConcept C141071460 @default.
• W2557095951 hasConcept C2776364478 @default.
• W2557095951 hasConcept C2776694085 @default.
• W2557095951 hasConcept C2778283404 @default.
• W2557095951 hasConcept C2779609412 @default.
• W2557095951 hasConcept C2781413609 @default.
• W2557095951 hasConcept C2911091166 @default.
• W2557095951 hasConcept C71924100 @default.
• W2557095951 hasConcept C90924648 @default.
• W2557095951 hasConceptScore W2557095951C126322002 @default.
• W2557095951 hasConceptScore W2557095951C141071460 @default.
• W2557095951 hasConceptScore W2557095951C2776364478 @default.
• W2557095951 hasConceptScore W2557095951C2776694085 @default.
• W2557095951 hasConceptScore W2557095951C2778283404 @default.
• W2557095951 hasConceptScore W2557095951C2779609412 @default.
• W2557095951 hasConceptScore W2557095951C2781413609 @default.
• W2557095951 hasConceptScore W2557095951C2911091166 @default.
• W2557095951 hasConceptScore W2557095951C71924100 @default.
• W2557095951 hasConceptScore W2557095951C90924648 @default.
• W2557095951 hasLocation W25570959511 @default.
• W2557095951 hasOpenAccess W2557095951 @default.
• W2557095951 hasPrimaryLocation W25570959511 @default.
• W2557095951 hasRelatedWork W1189657119 @default.
• W2557095951 hasRelatedWork W1971901954 @default.
• W2557095951 hasRelatedWork W1995369472 @default.
• W2557095951 hasRelatedWork W2344594786 @default.
• W2557095951 hasRelatedWork W2372143319 @default.
• W2557095951 hasRelatedWork W2414629529 @default.
• W2557095951 hasRelatedWork W2521262223 @default.
• W2557095951 hasRelatedWork W2530623633 @default.
• W2557095951 hasRelatedWork W2544724492 @default.
• W2557095951 hasRelatedWork W2556760360 @default.
• W2557095951 hasRelatedWork W2558837783 @default.
• W2557095951 hasRelatedWork W2560558845 @default.
• W2557095951 hasRelatedWork W2566193491 @default.
• W2557095951 hasRelatedWork W2567523609 @default.
• W2557095951 hasRelatedWork W2571931464 @default.
• W2557095951 hasRelatedWork W2592512558 @default.
• W2557095951 hasRelatedWork W2594361270 @default.
• W2557095951 hasRelatedWork W2791110402 @default.
• W2557095951 hasRelatedWork W2884725265 @default.
• W2557095951 hasRelatedWork W2979822115 @default.
• W2557095951 isParatext "false" @default.
• W2557095951 isRetracted "false" @default.
• W2557095951 magId "2557095951" @default.
• W2557095951 workType "article" @default.